=================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549
FORM 10-Q
QUARTERLY REPORT UNDER SECTION 13 OR 15(d)
OF THE SECURITIES ACT OF 1934
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For quarter ended: March 31, 1995
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from __________ to __________
Commission File Number: 0-17458
MBf USA, INC.
(Exact name of registrant as specified in its charter)
Oklahoma 73-1326131
(State or other jurisdiction (I.R.S. Employer
incorporation or organization) Identification No.)
Registrant's telephone number including area code: (201) 461-2382
Indicate by check mark whether the registrant (1) has filed
all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to
file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes [X] No [ ]
At May 12, 1995, there were 10,947,427 shares of Common Stock,
par value $0.01 per share, and 12,525,374 shares of Series A
Common Stock, par value $0.01 per share, outstanding.
=================================================================
<PAGE>
MBf USA, INC.
-------------
PART I - FINANCIAL INFORMATION
------------------------------
Item 1.
Consolidated Balance Sheets
March 31, 1995 and December 31, 1994.................pg. 1
Consolidated Statements of Operations
for the Three Months Ended March 31, 1995
and 1994.............................................pg. 3
Consolidated Statements of Cash Flows for the
Three Months Ended March 31, 1995 and 1994...........pg. 4
Notes to the Interim Consolidated Financial
Statements...........................................pg. 5
Item 2.
Management's Discussion and Analysis of Financial
Condition and Results of Operations..................pg. 8
PART II - OTHER INFORMATION
---------------------------
Item 6.
Exhibits and Reports on Form 8-K....................pg. 11
<PAGE>
MBf USA, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
March 31, 1995 December 31, 1994
-------------- -----------------
(Unaudited)
ASSETS
------
CURRENT ASSETS:
Cash and cash equivalents $ 50,088 $ 96,096
Accounts receivable - trade, net
of allowance for doubtful
accounts of $53,591 in 1995
and $40,591 in 1994 4,554,666 4,142,297
Note receivable from affiliate - 1,500,000
Inventories 6,290,025 7,377,808
Prepaid expenses 484,867 295,555
------------- -------------
Total current assets 11,379,646 13,411,756
------------- -------------
PROPERTY, PLANT AND EQUIPMENT:
Building improvements 21,744 21,744
Equipment, furniture and fixtures 422,045 281,830
------------- -------------
Total property, plant and
equipment 443,789 303,574
Less - Accumulated depreciation (150,744) (131,478)
------------- -------------
Property, plant and
equipment, net 293,045 172,096
------------- -------------
INVESTMENT IN LABORATORY
SPECIALISTS, INC. 1,059,367 1,059,367
------------- -------------
NET ASSETS OF DISCONTINUED SUBSIDIARY 158,936 209,111
------------- -------------
OTHER ASSETS:
Goodwill, net of accumulated
amortization of $268,664
in 1995 and $255,320 in 1994 1,481,336 1,494,680
Trademarks and license rights,
net of accumulated amortization
of $59,258 in 1995 and $52,077
in 1994 397,124 380,242
Due from affiliates/shareholders 506,979 1,232,830
Other assets 549,347 533,689
------------- -------------
Total other assets 2,934,786 3,641,441
------------- -------------
$ 15,825,780 $ 18,493,771
============= =============
The accompanying notes to consolidated financial statements are an
integral part of these balance sheets.
-1-
<PAGE>
MBf USA, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
March 31, 1995 December 31, 1994
-------------- -----------------
(Unaudited)
LIABILITIES AND SHAREHOLDERS' EQUITY
------------------------------------
CURRENT LIABILITIES:
Trade notes payable to bank $ 1,197,410 $ 1,201,315
Notes payable and current
portion of long-term
obligations 3,625,000 3,300,000
Accounts payable - trade 696,908 220,893
Due to affiliates/shareholders 3,181,988 5,848,700
Accrued expenses 846,491 946,515
------------- -------------
Total current liabilities 9,547,797 11,517,423
------------- -------------
LONG-TERM OBLIGATIONS 2,275,000 2,300,000
------------- -------------
DUE TO AFFILIATES 775,732 765,232
------------- -------------
SHAREHOLDERS' EQUITY
Series A common stock, $.01 par
value, 20,000,000 shares
authorized, 12,525,374 shares
issued and outstanding 125,253 125,253
Common Stock, $.01 par value,
40,000,000 shares authorized,
12,247,427 and 12,242,477
shares issued and outstanding
in 1995 and 1994, respectively 122,475 122,425
Additional paid-in capital 4,973,195 4,970,294
Retained Earnings (Deficit) (670,636) 16,180
Less - Common stock in treasury
at cost 1,300,000 shares in
1995 and 1994 (1,323,036) (1,323,036)
------------- -------------
Total shareholders' equity 3,227,251 3,911,116
------------- -------------
$ 15,825,780 $ 18,493,771
============= =============
The accompanying notes to consolidated financial statements are an
integral part of these balance sheets.
-2-
<PAGE>
MBf USA, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
For the Three Months
Ended March 31,
------------------------
1995 1994
---------- ----------
(Unaudited)
REVENUES:
Product sales, net $ 9,845,508 $ 7,435,615
Interest 56,438 2,158
Commission income - affiliates - 7,560
Other 67,012 7,961
------------ -----------
Total revenues 9,968,958 7,453,294
------------ -----------
COSTS AND EXPENSES:
Cost of product sales 8,697,622 6,079,742
Selling, general and administrative 1,741,492 894,824
Depreciation and amortization 53,297 33,325
Interest 154,926 71,325
------------ -----------
Total costs and expenses 10,647,337 7,079,216
------------ -----------
Income (loss) from continuing
operations before income from
investment and provision for
income taxes (678,379) 374,078
INCOME FROM INVESTMENT IN LSI - 79,374
------------ -----------
Income (loss) from continuing
operations before provision
for income taxes (678,379) 453,452
PROVISION FOR INCOME TAXES - -
------------ -----------
Income (loss) from continuing
operations (678,379) 453,452
DISCONTINUED OPERATIONS OF SUBSIDIARY (8,437) (594)
------------ -----------
Net Income (Loss) $ (686,816) $ 452,858
============ ===========
WEIGHTED AVERAGE NUMBER OF SHARES OF
COMMON STOCK AND COMMON STOCK
EQUIVALENTS OUTSTANDING 24,589,733 26,498,567
============ ===========
NET INCOME (LOSS) PER COMMON STOCK
AND COMMON STOCK EQUIVALENT $ (.028) $ .017
============ ===========
The accompanying notes to consolidated financial statements are an
integral part of these statements.
-3-
<PAGE>
MBf USA, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
For the Three Months
Ended March 31,
------------------------
1995 1994
---------- ----------
(Unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Income (Loss) $ (686,816) $ 452,858
Adjustments to reconcile net
income (loss) to net cash
provided by (used in) operating
activities:
Depreciation 19,266 11,805
Amortization 34,031 21,520
Provision for doubtful accounts 13,000 15,280
Loss from discontinued operations
of subsidiary 8,437 594
(Income) from investment in LSI - (79,374)
Changes in certain assets and
liabilities:
Accounts receivable - trade (425,369) 818,511
Inventories 1,087,783 (1,519,385)
Prepaid expenses (189,312) (172,545)
Accounts payable - trade 476,015 (308,774)
Accrued expenses (100,024) 250,164
------------ -----------
Net cash provided by (used in)
operating activities 237,011 (509,346)
------------ -----------
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures (140,215) (13,605)
Expenditures for other assets (53,227) (19,888)
Advances from discontinued subsidiary 41,738 555,197
------------ -----------
Net cash (used in) provided
by investing activities (151,704) 521,704
------------ -----------
CASH FLOWS FROM FINANCING ACTIVITIES:
Amounts due (from) to affiliates/
shareholders (430,361) 1,308,755
Proceeds from trade notes payable
to bank (3,905) (1,770,295)
Proceeds from notes payable 325,000 1,275,500
Net proceeds from warrant/stock
exercises 2,951 10,700
Payments on notes payable (25,000) (600,000)
------------ -----------
Net cash (used in) provided
by financing activities (131,315) 224,660
------------ -----------
NET INCREASE (DECREASE) IN CASH AND
CASH EQUIVALENTS (46,008) 237,018
------------ -----------
CASH AND CASH EQUIVALENTS, beginning
of period 96,096 580,191
------------ -----------
CASH AND CASH EQUIVALENTS, end of period $ 50,088 $ 817,209
============ ===========
The accompanying notes to consolidated financial statements are an
integral part of these statements.
-4-
<PAGE>
MBf USA, Inc.
NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS
March 31, 1995 and 1994
1. Basis of Presentation:
On February 27, 1992, the shareholders of American Drug
Screens, Inc. (an Oklahoma corporation, "the Company") approved a
transaction (the "Share Exchange") whereby the shareholder of
American Health Products Corporation (a Texas corporation, "AHP")
acquired control of the Company through a series of integrated
transactions: (a) the authorization of an additional 20,000,000
shares of common stock and the authorization of 12,525,374 shares
of Series A Common Stock, $0.01 par value ("Series A Common
Stock"), (b) the acquisition by a wholly owned subsidiary of the
Company, MBf America, Inc. (an Oklahoma corporation, "MAI") of
all the issued and outstanding shares of common stock of AHP, in
exchange for 12,525,374 shares of Series A Common Stock; and (c)
the restructuring of the Board of Directors by creating two
classes of directors. Accordingly, the transaction has been
accounted for as a purchase of the Company by AHP as of February
27, 1992, and AHP's shareholder's equity had been restated to
reflect the Series A Common Stock received in the Share Exchange
Agreement.
On May 21, 1993, the Company's shareholders approved the
Company's proposal to amend the Certificate of Incorporation
thereby changing the name of the Company to MBf USA, Inc. (the
"Company").
The interim financial statements are unaudited, but include
all adjustments (consisting solely of normal recurring
adjustments) which the Company considers necessary for a fair
presentation. The accompanying unaudited financial statements
are for interim periods and do not include all disclosures
normally provided in annual financial statements and should be
read in conjunction with the Company's audited financial
statements.
2. Description of Business
The accompanying consolidated financial statements include
the accounts of the Company and its subsidiaries AHP and Premier
Latex, Inc., which is currently inactive. All significant
intercompany transactions have been eliminated. The Company and
its subsidiaries market medical examination gloves in the U.S.,
and Playboy-brand condoms internationally.
Effective December 31, 1993, the Company adopted a plan to
discontinue operations and liquidate its wholly owned subsidiary,
Disposable Garments, Inc. ("DGI"). DGI, through its supply and
requirements agreement with Disposable Medical Products, Inc.
-5-
<PAGE>
("DMP"), distributed disposable medical garments to unaffiliated
customers.
Accordingly, DGI is reported as a discontinued operation in
the accompanying consolidated financial statements. Net assets
of the discontinued subsidiary at March 31, 1995 were $158,936,
which consisted primarily of inventory and receivables.
Laboratory Specialists, Inc. ("LSI") is an independent drug
testing laboratory which provides analysis for detection of
illegal drug use by employees and prospective employees. All of
the outstanding common stock of LSI was acquired by American Drug
Screens in 1989.
On April 18, 1994, the Company consummated an agreement to
transfer its common stock investment in LSI to its President and
former owner in exchange for the return of the Company's
1,300,000 shares of common stock held by him. Just prior to the
consummation of the sale, LSI declared a cash dividend of
$75,000, a non-cash dividend forgiving amounts due from the
Company of approximately $545,000 and a dividend of 706,244
shares of cumulative, redeemable, convertible preferred stock of
LSI with an interest rate set at the prime rate. Additionally,
the Company transferred its rights and all related assets in its
drug testing kit to LSI in exchange for a note payable to the
Company in the amount of $353,123 and an obligation to pay
royalties on related product sales for a period of five years.
The return of the Company's common stock has been accounted for
as the acquisition of treasury stock and, therefore, no gain or
loss was recognized.
In August 1994, the Company agreed to exchange its 706,244
shares of preferred stock in LSI valued at $706,244 for 239,405
shares of common stock of a newly formed corporation, Laboratory
Specialists of America, Inc. ("LSAI"), contingent upon LSAI
successfully completing an initial public offering ("IPO").
In September, 1994, LSAI successfully completed its IPO of
1,200,000 shares of common stock and currently trades under the
symbol ("LABZ") on the NASDAQ Small Cap Market System. The
Company has agreed not to sell its 239,405 shares of common stock
prior to July 8, 1996 without the prior consent of LSAI and
certain of its officers and directors. Thereafter, such shares
of common stock will be eligible for sale under Rule 144.
The Company's investment in the publicly traded stock of
LSAI is accounted for under the Statement of Financial Accounting
Standards No. 12 (SFAS 12). On May 16, 1995, the Company's
common stock investment in LSAI had a market value of $748,140.
Under SFAS 12, the Company's investment in LSAI is valued for
financial statement purposes, at the lower of cost or market, or
$706,244.
-6-
<PAGE>
As the Company's operations will no longer be in the drug
testing business, the accompanying consolidated financial
statements present the Company's investment in, and results of
operations from, LSI for 1995 and 1994 on an unconsolidated
basis.
3. Accounting for Income Taxes:
Effective January 1, 1993, the Company adopted Statement of
Financial Accounting Standards No. 109 (SFAS 109). SFAS 109
utilizes the liability method and deferred taxes are determined
based on the estimated future tax effects of differences between
the financial statement and tax basis of assets and liabilities
given the provision of enacted tax laws. Deferred income tax
provisions and benefits are based on the changes in the deferred
tax asset or tax liability from period to period. The effect of
adopting SFAS 109 was immaterial because at the date of adoption,
the Company had elected to carry forward existing net operating
losses for U.S. Federal income tax reporting purposes and
realization of existing deferred tax assets was not "more likely
than not." Accordingly, at the date of adoption, a valuation
reserve of approximately $382,000 was established.
Prior to implementation of SFAS 109, the Company accounted
for income taxes using Accounting Principles Board Opinion No. 11
(APB 11). Under APB 11, deferred income tax provisions and
benefits were recorded to reflect the tax consequences of timing
differences between the recording of income and expenses for the
financial reporting and income tax purposes at the tax rates in
effect when the differences arose.
The effective income tax rates differ from the statutory
Federal income tax rate of 34% at March 31, 1995. A
reconciliation of the statutory rate with the effective rate
follows:
1995 1994
---- ----
Tax expense at statutory rate of 34% $(233,517) $154,174
Goodwill amortization 11,570 7,317
State income taxes (48,077) -
Other 270,024 -
Utilization of Net Operating Loss
Carryforwards (161,491)
--------- --------
$ -0- $ -0-
--------- --------
The Company had net operating loss carryforwards ("NOLs") at
December 31, 1994 of approximately $1,300,000 which were
available to reduce Federal taxable income in future periods and
will begin expiring in 2003. In accordance with Federal tax
regulations, usage of NOLs is subject to limitations in future
years if certain ownership changes occur. Such ownership changes
occurred with the
-7-
<PAGE>
transactions described in Note 1. Because of these factors, the
utilization of the remaining NOLs may be significantly limited.
ITEM 2.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS.
Total revenues for the first quarter ended March 31, 1995
were $9,968,958 compared to $7,453,294 for the same period in
1994, an increase of 33.8%. First quarter 1995 revenues
consisted of $9,545,284 from the Company's latex glove product
line sold by the Company's subsidiary AHP and $300,222 from the
Playboy condom product line. Sales for AHP and Playboy for the
comparable period in 1994 were $7,007,893 and $421,722,
respectively.
The increased sales volume on a comparable basis at AHP is
attributable to more developed customer relationships, an
expansion of the AHP sales force, and larger than normal orders
placed by major customers in anticipation of an industry wide
price increase due to the rising price of latex raw materials.
During the first quarter of 1995, the Company's principal glove
suppliers MBf Rubber and MBf Health experienced under-production
problems resulting in significantly lower shipments than required
by AHP. In addition, the prices charged by MBf Health to AHP
during the quarter ended March 31, 1995 were 18% higher than the
effective net prices charged to AHP during the previous three
year period which was governed by the terms of the Share
Exchange. The Company believes the current prices charged by MBf
Health to AHP are higher than those of competitors selling
comparable quantities of gloves to suppliers in the United
States.
The Company is currently experiencing difficulty meeting its
customers' orders for both powdered and powder-free latex exam
gloves. On May 19, 1995, the Company signed an agreement with an
unaffiliated supplier to supply powder-free examination gloves.
Continuation of the under-production problem at MBf Health and
the inability of AHP to obtain more competitive pricing from MBf
Health would have a material adverse effect on the Company since
there is a limited manufacturing capacity from which to obtain
gloves from other sources.
The decrease in sales of Playboy condoms on a comparable
period basis is attributable to one large opening order placed in
the Taiwan market in 1994 compared to several smaller orders and
re-orders in Taiwan in 1995. Currently, the Company has signed
distribution agreements in 18 countries compared to two
agreements at the same time in 1994. The Company expects sales
levels to grow significantly beginning in the second quarter of
1995 and
-8-
<PAGE>
anticipates that several large opening orders will be shipped to
markets in South America and Eastern Europe.
Cost of goods sold as percentage of sales for the period
ended March 31, 1995 was 88.3% compared to 81.8% for the same
quarter in the prior year. The significant increase in cost of
sales as a percentage of sales is attributable to the 18% price
increase charged by MBf Health to AHP, coupled with the inability
of AHP to pass on this increase due to market conditions.
Selling, general and administrative expense increased from
$894,824 for the quarter ended March 31, 1994 to $1,741,492 for
the same period in 1995. The current level of selling, general
and administrative expense is comparable to expenses incurred by
the Company during the third and fourth quarters of 1994. The
increase on a comparable level over the first quarter in 1994 is
attributable to costs associated with the introduction of Playboy
condoms in new countries, an increase in selling expenses at AHP
commensurate with its growth, and expenses associated with the
anticipated launch of the Company's nutritional product line in
the second quarter of 1995.
Interest expense increased from $71,325 for the quarter
ended March 31, 1994 compared to $154,926 for the same period in
1995. The increase is attributable to an increase in the prime
rate and higher levels of borrowing in 1995 compared to 1994.
LIQUIDITY AND CAPITAL RESOURCES
At March 31, 1995, the Company had a working capital surplus
of $1,831,849 compared to a $1,894,333 surplus at December 31,
1994. The decrease in working capital is primarily attributable
to reclassification of certain long term affiliate receivables to
current assets, offset by a net loss of $686,816.
On March 29, 1995, Bank Bumiputra Malaysia Berhad ("BBMB")
modified and extended AHP's credit lines until October 31, 1997.
The credit facility of $13,000,000 is comprised of a revolving
line of credit of $6,000,000, a letter of credit facility for
$2,000,000, and a $5,000,000 term loan, the availability of which
is limited to use in connection with the possible acquisition of
the MBf Health manufacturing facility.
The line of credit bears interest at three percent (3%) over
prime, and the term loan bears interest at three and one-half
percent (3.5%) over prime. The entire facility, which is
guaranteed by MBf Holdings, the principal shareholder of the
Company, is secured by accounts receivable and inventory and is
governed by specific financial covenants and ratios. At December
31, 1994, $3,175,000 of the credit line and $1,201,315 of the
letter of credit facility had been utilized. At March 31, 1995,
-9-
<PAGE>
$3,525,000 of the credit line and $1,197,410 of the letter of
credit facility had been utilized. No portion of the $5,000,000
term loan has been utilized.
In October 1994, pursuant to two debenture and warrant
purchase agreements between the Company and two trusts
established by George S. Mennen, the Company issued, and each
trust purchased, a convertible subordinated debenture in the
amount of $1,000,000 payable in seven years with interest at one
and one-half percent (1.5%) over the prime rate. Each debenture
is convertible into Common Stock of the Company at a conversion
price of $2.50 per share. In addition, each trust received a
warrant exercisable over five (5) years to purchase 75,000 shares
of the Common Stock of the Company at an exercise price of $2.25
per share.
Proceeds from these debentures were used to fund the Playboy
condom inventory, nutritional products inventory and start-up
expenses associated with both products. For the period ended
March 31, 1995 the Company incurred interest expense of $50,932
on this indebtedness.
In December 1994, the Company loaned to an affiliate, MACC
Trading Limited, on a short term basis, the principal amount of
$1,500,000. This loan was secured by the Company's obligation to
MACC Trading Limited under the parties December 30, 1993 purchase
agreement for the acquisition by the Company of the Playboy
condom license rights from MACC Trading Limited. This loan bore
interest at the rate of four percent (4%) over prime. On May 5,
1995, the Company and MBf Holdings (the parent company of MACC
Trading) entered into an agreement pursuant to which the
Company's subsidiary, AHP, offset the MACC Trading receivable
along with the accrued interest thereon ($1,572,688) against the
trade payable balance owed by AHP to MBf Health, an indirect
subsidiary of MBf Holdings, resulting in the effective repayment
of the loan on May 5, 1995.
Due to losses incurred at AHP for the period ended March 31,
1995, the Company was in violation of its minimum net worth
covenant of its BBMB loan for its AHP subsidiary at March 31,
1995. The Company believes it will be able to negotiate a
modification of this covenant with BBMB during the next thirty
days.
The Company believes that it has sufficient liquidity to
fund the Company's operation for the immediate future.
-10-
<PAGE>
ITEM 6.
EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits
--------
27. Financial Data Schedule.
(b) Reports on Form 8-K
-------------------
None.
-11-
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933,
the registrant has duly caused this Form 10-Q to be signed on its
behalf by the undersigned, thereunto duly authorized, on the 23rd
day of May, 1995.
MBf USA, Inc.
an Oklahoma Corporation
By: /s/ David Natan
---------------------
David Natan
Chief Financial Officer
<PAGE>
EXHIBIT INDEX
Exhibit
-------
27. Financial Data Schedule
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
THE SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED
FROM MBf USA, INC. FORM 10-Q FOR THE QUARTER ENDED MARCH 31, 1995
AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL
STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1995
<PERIOD-END> MAR-31-1995
<CASH> 50
<SECURITIES> 0
<RECEIVABLES> 4,608
<ALLOWANCES> (54)
<INVENTORY> 6,290
<CURRENT-ASSETS> 11,380
<PP&E> 444
<DEPRECIATION> (151)
<TOTAL-ASSETS> 15,826
<CURRENT-LIABILITIES> 9,548
<BONDS> 0
<COMMON> 248
0
0
<OTHER-SE> 2,979
<TOTAL-LIABILITY-AND-EQUITY> 15,826
<SALES> 9,846
<TOTAL-REVENUES> 9,969
<CGS> 8,698
<TOTAL-COSTS> 1,781
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 13
<INTEREST-EXPENSE> 155
<INCOME-PRETAX> (678)
<INCOME-TAX> 0
<INCOME-CONTINUING> (678)
<DISCONTINUED> (9)
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (687)
<EPS-PRIMARY> 0
<EPS-DILUTED> (.028)
</TABLE>
